tradingkey.logo
搜尋

ENDRA Life Sciences Inc

NDRA
添加自選
4.610USD
+0.280+6.47%
收盤 07-31 16:00美東報價延遲15分鐘
5.42M總市值
虧損本益比TTM

ENDRA Life Sciences Inc

4.610
+0.280+6.47%

關於 ENDRA Life Sciences Inc 公司

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.

ENDRA Life Sciences Inc簡介

公司代碼NDRA
公司名稱ENDRA Life Sciences Inc
上市日期Jun 28, 2017
CEOTokman (Alexander Y)
員工數量21
證券類型Ordinary Share
年結日Jun 28
公司地址3600 Green Ct Ste 350
城市ANN ARBOR
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編48105
電話17343350468
網址https://www.endrainc.com/
公司代碼NDRA
上市日期Jun 28, 2017
CEOTokman (Alexander Y)

ENDRA Life Sciences Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
76.27K
+7.06%
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
33.46K
+40.23%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
-1500000.00%
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-3016200.00%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
76.27K
+7.06%
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
33.46K
+40.23%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
-1500000.00%
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-3016200.00%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--

常見問題

ENDRA Life Sciences Inc的前五大股東是誰?

ENDRA Life Sciences Inc的前五大股東如下:Mr. Anthony DiGiandomenico

有多少機構持有ENDRA Life Sciences Inc(NDRA)的股份?

截至2026Q1,共有30家機構持有ENDRA Life Sciences Inc的股份,合計持有的股份價值約為218.33K,占公司總股份的17.60% 。與2025Q4相比,機構持股有所增加,增幅為137855.00。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有